Singapore Institute of Advanced Medicine (SGX:9G2) has extended its negotiations with EnGeneIC for a partnership after positive developments in EnGeneIC's dream vector technology, according to a Tuesday filing on the Singapore Exchange.
The parties agreed to extend the timeline for finalizing a definitive agreement by 60 days, now set for Feb. 1, 2025. The scope of the collaboration may expand to include EDV-based theranostics and boron capture therapy. All other terms remain unchanged.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments